Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update reports results for frontline therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma comparing ibrutinib plus ven…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)
• Leukeran (chlorambucil)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-28